Desmopressin treatment for a case of dengue hemorrhagic fever/dengue shock syndrome [4]

Clinical Infectious Diseases

Volumn 33, Issue 9, 2001, Pages 1611-1612

  Pea, Laurent ^a   Roda, Laurent ^a   Moll, Fabrice ^a  

^a Centre Hospitalier Territorial Papeete   (French Polynesia)

Author keywords

[No Author keywords available]

Indexed keywords

DESMOPRESSIN;

CASE REPORT; CLINICAL FEATURE; DENGUE; DENGUE SHOCK SYNDROME; DISEASE COURSE; HUMAN; HYPOVOLEMIC SHOCK; INTENSIVE CARE; LETTER; MALE; PRIORITY JOURNAL; SCHOOL CHILD; SYMPTOM; THROMBOCYTOPENIA;

CHILD; DEAMINO ARGININE VASOPRESSIN; DENGUE HEMORRHAGIC FEVER; HUMANS; MALE; RENAL AGENTS; TREATMENT OUTCOME;

EID: 0035503320     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/323013     Document Type: Letter

References (9)

1. Fluid replacement in dengue shock syndrome: A randomized, double-blind comparison of 4 intravenous-fluid regimens
2. Editorial response: Resuscitation of patients with dengue fever/dengue shock syndrome
3. Dengue hemorrhagic fever: A public health problem and a field for research
4. Current status of non-transfusional haemostatic agents
5. Desmopressin (DDAVP) in the treatment of bleeding disorders: The first 20 years
6. 1-Desamino-8-arginine-vasopressin corrects the hemostatic defects in type 2B von Willebrand's disease
7. DDAVP is not a panacea for children with bleeding disorders
8. Failure of carbazochrome sodium sulfonate (AC-17) to prevent dengue vascular permeability or shock: A randomised, controlled trial
9. Protection against plasma leakage in dengue haemorrhagic fever by infusion of carbazochrome sodium sulfonate (AC-17)